These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35771887)
1. Actovegin in the management of patients after ischemic stroke: A systematic review. la Fleur P; Baizhaxynova A; Reynen E; Kaunelis D; Galiyeva D PLoS One; 2022; 17(6):e0270497. PubMed ID: 35771887 [TBL] [Abstract][Full Text] [Related]
2. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Guekht A; Skoog I; Edmundson S; Zakharov V; Korczyn AD Stroke; 2017 May; 48(5):1262-1270. PubMed ID: 28432265 [TBL] [Abstract][Full Text] [Related]
3. PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke. Anghelescu A; Firan FC; Onose G; Munteanu C; Trandafir AI; Ciobanu I; Gheorghița Ș; Ciobanu V Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371718 [TBL] [Abstract][Full Text] [Related]
4. Citicoline for treating people with acute ischemic stroke. Martí-Carvajal AJ; Valli C; Martí-Amarista CE; Solà I; Martí-Fàbregas J; Bonfill Cosp X Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013066. PubMed ID: 32860632 [TBL] [Abstract][Full Text] [Related]
6. The use of Ginkgo biloba extract in acute ischemic stroke. Liu J Explore (NY); 2006 May; 2(3):262-3. PubMed ID: 16781654 [TBL] [Abstract][Full Text] [Related]
7. Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin Firan FC; Romila A; Onose G Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365943 [TBL] [Abstract][Full Text] [Related]
11. Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Derev'yannykh EA; Bel'skaya GN; Knoll EA; Krylova LG; Popov DV Neurosci Behav Physiol; 2008 Oct; 38(8):873-5. PubMed ID: 18802768 [TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Liu J; Wang LN Cochrane Database Syst Rev; 2015 Oct; (10):CD010693. PubMed ID: 26511368 [TBL] [Abstract][Full Text] [Related]
14. Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Boncoraglio GB; Del Giovane C; Tramacere I Stroke; 2021 Jun; 52(6):1974-1982. PubMed ID: 33902303 [TBL] [Abstract][Full Text] [Related]
15. Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Brown DL; Levine DA; Albright K; Kapral MK; Leung LY; Reeves MJ; Sico J; Strong B; Whiteley WN; Stroke; 2021 Jul; 52(7):e468-e479. PubMed ID: 34024115 [TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Liu J; Wang LN Cochrane Database Syst Rev; 2014 Jan; (1):CD010693. PubMed ID: 24399670 [TBL] [Abstract][Full Text] [Related]
17. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. Li ZX; Xiong Y; Gu HQ; Fisher M; Xian Y; Johnston SC; Wang YJ Stroke; 2021 Jul; 52(7):2250-2257. PubMed ID: 34039032 [TBL] [Abstract][Full Text] [Related]